Attached files
| file | filename |
|---|---|
| EX-10.17 - AMENDMENT TO AMENDED AND RESTATED EMPLOYMENTAGREEMENT, DATED OCTOBER 29, 2018, B - ORAMED PHARMACEUTICALS INC. | f10k2018ex10-17_oramedpharma.htm |
| EX-32.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC. | f10k2018ex32-1_oramedpharma.htm |
| EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC. | f10k2018ex31-2_oramedpharma.htm |
| EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC. | f10k2018ex31-1_oramedpharma.htm |
| EX-23.1 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLICACCOUNTING FIRM - ORAMED PHARMACEUTICALS INC. | f10k2018ex23-1_oramedpharma.htm |
| EX-10.24 - REPRESENTATIVE FORM OF INDEMNIFICATION AGREEMENTSBETWEEN ORAMED PHARMACEUTICALS - ORAMED PHARMACEUTICALS INC. | f10k2018ex10-24_oramedpharma.htm |
| EX-10.18 - EMPLOYMENT AGREEMENT, DATED NOVEMBER 6, 2018,BY AND BETWEEN ORAMED LTD. AND MARK - ORAMED PHARMACEUTICALS INC. | f10k2018ex10-18_oramedpharma.htm |
| 10-K - ANNUAL REPORT - ORAMED PHARMACEUTICALS INC. | f10k2018_oramedpharma.htm |
Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended August 31, 2018, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Hilla Eisenberg, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
| 1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Dated: November 27, 2018 | /s/ Hilla Eisenberg |
|
Hilla Eisenberg Chief Financial Officer |